Lung Cancer Living Room™

In this episode Dr. Ross Camidge of University of Colorado, Denver participates in a groundbreaking Q&A where he covers many exciting new developments in Lung Cancer- including Immune Stimulant Response Drugs, new findings related to tumor cell heterogeneity, and perhaps most importantly, ways to ensure that you aren't receiving falsely negative results on your Molecular Tests. Dr. Camidge explains how these tests (specifically for EGFR & ALK) work and how to make sure that you are not being given "Sequential Testing", meaning that they quit testing for other mutations as soon as they get a positive result on one. Furthermore, he explains how to be sure you're tested for EVERY form of each mutation and not just the most common forms in the most common places (in the case of EGFR). He explains "Wild Type" cancers and gives great new insight into what could be driving them along with some strategies for treatment. He also discusses when to rebiopsy and how it could lead to new treatment possibilities given new developments in the understanding of how cancers change over time. As much as it's filled with practical information, this episode is also filled with HOPE- including new uses for Crizotinib ("the gift that keeps on giving"), the new drug on the horizon, Afatinib (EGFR/ HER-2/ HER-4 inhibitor), exciting take on what's behind the "Unknown" section of the pie chart defining the molecular drivers of cancer growth, and his prediction of a blood test for early screening for lung cancer. Special thanks to Funding Partner, GENENTECH.